Comparing BMS-986393 with standard treatments for relapsed multiple myeloma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to evaluate the efficacy and safety of BMS-986393 compared to standard treatment regimens in adults with relapsed or refractory multiple myeloma who are also refractory to lenalidomide. Participants will receive either the investigational drug or standard therapies, including cyclophosphamide, fludarabine, daratumumab, and pomalidomide. The study will assess treatment outcomes and side effects to determine the potential advantages of BMS-986393 in this patient population.

Why it matters

Who can join: the full rules

Inclusion Criteria

* Participants must have relapsed or refractory multiple myeloma (RRMM).
* Participants must have received at least 1 but no greater than 3 prior multiple myeloma (MM) regimens which may include a proteasome inhibitor (PI), an immunomodulatory drug (IMiD), and an anti-CD38 monoclonal antibody and have prior exposure to lenalidomide.
* Participants must have a documented diagnosis of MM as per International Myeloma Working Group Criteria.
* Participants must have measurable disease during screening.
* Participants must have adequate organ function.
* Participants must have an Eastern Cooperative Oncology group performance status 0 or 1.

Exclusion Criteria

* Participants must not have known active or history of central nervous system (CNS) involvement of Multiple Myeloma (MM).
* Participants must not have solitary plasmacytomas or non-secretory myeloma without other evidence of measurable disease.
* Participants must not need urgent treatment due to rapidly progressing MM.
* Other protocol-defined Inclusion/Exclusion criteria apply.

Where it's running

• University of Alabama at Birmingham
  Birmingham, Alabama, United States Recruiting
• UCLA Hematology/Oncology - Santa Monica
  Los Angeles, California, United States Recruiting
• University of California, Irvine (UCI) Health - UC Irvine Medical Center
  Orange, California, United States Recruiting
• Georgetown University Medical Center
  Washington D.C., District of Columbia, United States Recruiting
• Baptist MD Anderson Cancer Center
  Jacksonville, Florida, United States Recruiting
• University of Miami Hospital and Clinics, Sylvester Cancer Center
  Miami, Florida, United States Recruiting

+91 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
• Email: Clinical.Trials@bms.com
• Phone: 855-907-3286

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• In Vivo PICX CAR-T Therapy for Relapsed or Refractory Multiple Myeloma

  A single-arm study is testing an in vivo CAR-T cell therapy (PICX Injection) to see if it is safe and can help people with relapsed or refractory multiple myeloma.

  Recruiting Phase 1 Chongqing Precision Biotech Co., Ltd · Kunming, Yunnan · NCT07715630

• F182112 versus standard care for relapsed or refractory multiple myeloma

  This study will test whether F182112 works better than standard treatments for adults whose multiple myeloma has come back or stopped responding after prior therapies including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody.

  Recruiting Phase 3 Shandong New Time Pharmaceutical Co., LTD · Tianjing · NCT07579234

• Dual-target BCMA and GPRC5D CAR-T for relapsed/refractory multiple myeloma with extramedullary disease

  This will try a CAR-T cell treatment that targets both BCMA and GPRC5D for adults whose relapsed or refractory multiple myeloma has spread outside the bone marrow.

  Recruiting Phase 1 Beijing GoBroad Hospital · Shanghai · NCT07003568

• Dual-target BCMA–CD19 CAR-T therapy for relapsed or refractory multiple myeloma with extramedullary disease

  This trial will try a CAR-T treatment that targets both BCMA and CD19 for adults whose relapsed or refractory multiple myeloma has spread outside the bone marrow.

  Recruiting Phase 1 Beijing GoBroad Hospital · Shanghai · NCT07003555

• Using patients' own modified immune cells to treat certain blood cancers

  This study is testing a new treatment using modified immune cells to see if it can help people with certain blood cancers like multiple myeloma, leukemia, and lymphoma.

  Recruiting Anhui Provincial Hospital · Hefei · NCT06961669

• Combining Purinostat Mesylate with Pomalidomide and Dexamethasone for Multiple Myeloma

  This study is testing if a new combination of medications can be safely used to help people with relapsed or hard-to-treat multiple myeloma.

  Recruiting Phase 1/2 Chengdu Zenitar Biomedical Technology Co., Ltd · Chengdu, Sichuan · NCT06484829

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.